As Hem-Onc Fellows Network , #bcsm management has become increasingly complex! Below is a #study guide for #MedOnc #MedEd fellows I have been working on : What do you think? 🧐 Ilana Schlam Paolo Tarantino Oncology Brothers Roberto Leon-Ferre 🛑 #WorkinProgress #NotMedicalAdvice 🙏 #InputsWelcome

Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published nature nature.com/articles/s4158… MD Anderson Cancer Center

It was a great pleasure to have attended #NCCN 2023 annual meeting and presented our Hem-Onc educational QI project RWMC Internal Medicine Residency doi.org/10.6004/jnccn.… #NCCN2023 #hematology #oncology #internalmedicine #education #MedTwitter

A watershed moment for #MDSsm Myelodysplastic syndromes with the first approval of a targeted therapy, the first approval in relapsed/refractory setting, & opens the door widely for precision medicine in MDS. FDA approves ivosidenib for MDS fda.gov/drugs/resource…

CD Marker Mathematics CD34+ = Blast CD3+ = T-cell CD19+ = B-cell CD33+ = Myeloid Then do addition! CD34+ = Acute leukemia CD34+ CD19+ = B-ALL CD34+ CD3+ = T-ALL CD34+ CD33+ = AML CD34- CD33+ = APL (promyelocyte one step above blast) For more details docs.abcam.com/pdf/immunology…

Had a blast at the #ASH23 Trainee welcome reception! Petco Park @Hemonctrainee Georgio Medawar, MD Pavlina Chrysafi @aframirez_g

Weekend review 📖 What is the right duration of VENETOCLAX with HMA for AML: 7 days vs 14 days vs 21 days or 28 days? Brief review of literature in this 🧵 #leusm #AML

🚨Out in Journal of the @NCCN update the management of #CML 💰 Price of TKIs 💊 Frontline & Salvage therapies ⬇️ Lower TKIs doses ⚠️ Causes of treatment failure 💡 Third-generation TKIs ‼️All you need to know below ⬇️⬇️ #leusm OncoAlert Hagop Kantarjian,MD MD Anderson Cancer Center jnccn.org/view/journals/…

Having 2 classification systems is a disservice to all involved. I just spent 30 min explaining to a patient why her path report had AML by 1 system & MDS by other, & why trial eligibility depends on system. If 2 systems cannot be reconciled urgently, we should just vote for one

Venetoclax Combo Safe, Effective in AML Patients Age 80 and Up, Real-World Data Show | Thanks MedPage Today for highlighting our ⁦Sylvester Comprehensive Cancer Center⁩ study! ⁦Justin Watts MD⁩ ⁦Ellen Madarang⁩ ⁦Mikkael A. Sekeres MD, MS⁩ ⁦Sangeetha Venugopal MD,MS⁩ #leusm medpagetoday.com/hematologyonco…

Patients achieving MRD negativity in blood after second induction show no survival benefit from CR1 transplant, even if FLT3-ITD comutated. ow.ly/I1GM50RASNQ #clinicaltrialsandobservations #myeloidneoplasia #transplantion

Grateful to have collaborated on this! Talha Badar Alexander Coltoff, MD #leusm #ALL #MRD library.ehaweb.org/eha/2024/eha20…

Nothing like retrospective chart review of AML pts to put one’s own life in perspective!!! 😔 What a blessing it is to be healthy and alive! Nothing else compares…. 🍀 I am hopeful that in our lifetime we will see a cure for this devastating disease!!! but more 💵 for #AML

Asciminib Shows Superiority Over Available Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia dailynews.ascopubs.org/do/asciminib-s…

Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval ascopubs.org/doi/10.1200/JC…